drugset
drugset / Trial / NCT01910220

Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)

NCT01910220 ↗

Phase 1 Completed 125 enrolled Regeneron Pharmaceuticals Sanofi · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a study to assess the safety and bioeffect of REGN1033 (SAR391786) in healthy volunteers.

Timeline

Start
2013-08
Primary completion
2014-06
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Trevogrumab Monoclonal antibody — —

Indications

No indication recorded.